In This Article:
As European markets show signs of recovery, bolstered by the European Central Bank's interest rate cuts and a delay in higher tariffs, investors are keenly observing opportunities that may arise from these developments. In such an environment, identifying stocks that are potentially undervalued can be crucial for investors looking to capitalize on market movements while considering factors like economic policy shifts and trade uncertainties.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Cenergy Holdings (ENXTBR:CENER) | €8.42 | €16.49 | 48.9% |
| BFF Bank (BIT:BFF) | €7.50 | €14.39 | 47.9% |
| Mips (OM:MIPS) | SEK352.60 | SEK690.34 | 48.9% |
| LPP (WSE:LPP) | PLN15610.00 | PLN30721.86 | 49.2% |
| Lindab International (OM:LIAB) | SEK186.80 | SEK372.09 | 49.8% |
| TF Bank (OM:TFBANK) | SEK345.50 | SEK683.33 | 49.4% |
| Verbio (XTRA:VBK) | €9.24 | €18.25 | 49.4% |
| Stille (OM:STIL) | SEK209.00 | SEK400.62 | 47.8% |
| Komplett (OB:KOMPL) | NOK11.50 | NOK22.81 | 49.6% |
| Fodelia Oyj (HLSE:FODELIA) | €7.14 | €13.91 | 48.7% |
Let's review some notable picks from our screened stocks.
Almirall
Overview: Almirall, S.A. is a biopharmaceutical company specializing in skin health, operating across multiple regions including Spain, Europe, the Middle East, the United States, Asia, and Africa with a market cap of approximately €2 billion.
Operations: The company's revenue segments include €97.23 million from commercial areas through licensees, €808.38 million from its own network in Europe, and €55.43 million from its own network in the United States.
Estimated Discount To Fair Value: 39%
Almirall is trading at €9.37, significantly below its estimated fair value of €15.37, suggesting it may be undervalued based on cash flows. The company's revenue is expected to grow 9.5% annually, outpacing the Spanish market's 5% growth rate, with earnings forecasted to increase by 35.8% per year over the next three years. Recent profitability and executive changes indicate a strategic focus on maintaining growth momentum in medical dermatology across Europe.
Borregaard
Overview: Borregaard ASA develops, produces, and markets specialized biochemicals and biomaterials globally with a market cap of NOK16.53 billion.
Operations: The company's revenue segments consist of Bio Materials at NOK2.62 billion, Bio Solutions at NOK4.24 billion, and Fine Chemicals at NOK799 million.